AA
ABUS icon

AlphaCentric Advisors’s Arbutus Biopharma ABUS Stock Holding History

AlphaCentric Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-47,925
Closed -$231K – 253
2025
Q4 		$231K Buy
+47,925
New +$216K 0.23% 133

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

AlphaCentric Advisors's ABUS Position: Q1 2026 in Review

AlphaCentric Advisors sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 47,925 shares — an estimated $231K sold.

AlphaCentric Advisors first reported a position in ABUS in Q4 2025 and held it in 1 quarter. The position peaked at $231K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • AlphaCentric Advisors reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • AlphaCentric Advisors sold 47,925 Arbutus Biopharma shares in Q1 2026, an estimated $231K.
  • AlphaCentric Advisors first reported a position in Arbutus Biopharma in Q4 2025 and held it in 1 quarter.
  • AlphaCentric Advisors's Arbutus Biopharma position peaked at $231K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.